AEterna Zentaris (AEZS) : Traders are bullish on AEterna Zentaris (AEZS) as it has outperformed the S&P 500 by a wide margin of 2.3% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.23%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.67% in the last 1 week, and is up 4.85% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
AEterna Zentaris (NASDAQ:AEZS): The stock opened at $3.47 on Friday but the bulls could not build on the opening and the stock topped out at $3.50 for the day. The stock traded down to $3.40 during the day, due to lack of any buying support eventually closed down at $3.46 with a loss of -0.29% for the day. The stock had closed at $3.47 on the previous day. The total traded volume was 84,570 shares.
The stock has recorded a 20-day Moving Average of 0.77% and the 50-Day Moving Average is 0.62%. Aeterna Zentaris Inc. is up 1.17% in the last 3-month period. Year-to-Date the stock performance stands at -22.77%.
AEterna Zentaris (AEZS) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $12 and the lowest price target forecast is $10. The average forecast of all the analysts is $11 and the expected standard deviation is $0.82.
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and womens health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.